Evidence map›Paper›PMID 32275203›Full record

ArticleVirology2020

Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.

Bongiwe Ndlovu, Kamini Gounder, Daniel Muema, Nagarajan Raju, Tandile Hermanus, Qiniso Mthethwa, Kim Robertson, Bruce D Walker, Ivelin S Georgiev, Lynn Morris and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Bongiwe NdlovuHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Electronic address: Ndlovub3@ukzn.ac.za.
Kamini GounderHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Africa Health Research Institute, Durban, South Africa. Electronic address: kgounder25@gmail.com.
Daniel MuemaAfrica Health Research Institute, Durban, South Africa. Electronic address: muemadk@gmail.com.
Nagarajan RajuVanderbilt Vaccine Center and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: raju.nagarajan@vanderbilt.edu.
Tandile HermanusCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. Electronic address: tandileh@nicd.ac.za.
Qiniso MthethwaHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Electronic address: qiniso.mthethwa@gmail.com.
Kim RobertsonHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Electronic address: kimmir@gmail.com.
Bruce D WalkerHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. Electronic address: bwalker@mgh.harvard.edu.
Ivelin S GeorgievVanderbilt Vaccine Center and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: ivelin.georgiev@vanderbilt.edu.
Lynn MorrisCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; University of the Witwatersrand, Johannesburg, South Africa. Electronic address: lynnm@nicd.ac.za.
Penny L MooreCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; University of the Witwatersrand, Johannesburg, South Africa. Electronic address: pennym@nicd.ac.za.
Thumbi Ndung'uHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Africa Health Research Institute, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Max Planck Institute for Infection Biology, Berlin, Germany; Division of Infection and Immunity, University College London, UK. Electronic address: ndungu@ukzn.ac.za.
National Health Laboratory Service · ZAAfrica Health Research Institute · ZARagon Institute of MGH, MIT and Harvard · USUniversity of KwaZulu-Natal · ZAVanderbilt University Medical Center · USCentre for the AIDS Programme of Research in South Africa · ZA

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Neutralization Fingerprinting Analysis of Polyclonal Antibody Responses against HIV-1R01AI131722 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GEORGIEV, IVELIN · 2017 to 2021
$4.5M
FIC NIH HHS D43 TW010543Howard Hughes Medical InstituteNIAID NIH HHS R01 AI131722Wellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) may constitute an essential component of a protective vaccine against HIV-1, yet no immunogen has been able to elicit them. To characterize the development of bNAbs in HIV-1 subtype C infected individuals, a panel of 18 Env-pseudotyped viruses was used to screen 18 study participants. The specificity of plasma neutralization was mapped against Env mutants and MPER chimeras. Envelope (env) gene sequence evolution was characterized by single genome amplification and sequencing. Three out of eighteen individuals developed broad plasma neutralizing activity (>60% breadth). Two of the three participants may target epitopes comprising glycans at position 276 of the D loop in the CD4 binding site and 332 glycan supersite, respectively. Deletion of these glycans was associated with neutralization resistance. Our study describes the kinetics of the development of plasma neutralizing activity and identified amino acid residue changes suggestive of immune pressure on putative epitopes. The study enhances our understanding of how neutralization breadth develops in the course of HIV-1 subtype C infection.

Indexed as

Amino Acid SequenceAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitope MappingHIV-1HIV AntibodiesHIV InfectionsHumansAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesBroadly neutralizing antibodiesEnvelope sequencingEpitope mapping

Identifiers

PMID32275203
PMCPMC8186003
OpenAlexW3012976772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.